tumor
necrosi
factor
tnfa
cytokin
infecti
agent
shown
exert
direct
pleiotrop
properti
induc
varieti
antivir
effect
although
low
level
tnfa
patholog
situat
includ
viral
infect
contribut
cell
protect
excess
amount
may
work
analyz
express
tnfa
gene
pacaus
cell
damag
tient
chronic
hepat
c
serum
tnfa
level
biosynthesi
tnfa
tightli
regul
found
elev
chronic
hepat
c
patient
transcript
posttranscript
mechan
includ
case
present
sustain
biochem
varieti
virus
shown
induc
remiss
diseas
interferon
therapi
unexpress
tnfa
vitro
accumul
treat
patient
chronic
hepat
c
show
intnfa
messeng
rna
mrna
occur
viruscreas
tnfa
messeng
rna
mrna
level
liver
mononuclear
cell
compar
healthi
infect
cell
may
result
increas
trancontrol
complet
treatment
interferon
scription
stabil
transcript
accumupati
experienc
sustain
complet
respons
lation
tnfa
mrna
prime
cell
enhanc
show
valu
tnfa
mrna
liver
releas
bioactiv
tnfa
respons
inperipher
mononuclear
cell
within
normal
rang
ducer
cytokin
bacteri
product
significantli
lower
patient
respond
tnfa
involv
pathogenesi
interferon
complet
respons
divers
liver
condit
includ
viral
hepatirelaps
interferon
withdraw
pretreat
valti
increas
product
tnfa
peripher
ue
tnfa
mrna
lower
longterm
respond
interferon
case
fail
respond
blood
mononuclear
cell
pbmc
observ
treatment
valu
tnfa
mrna
liver
fulmin
viral
hepat
chronic
hepat
b
mononuclear
cell
higher
specimen
posiin
chronic
nona
nonb
hepat
recent
rais
tive
hepat
c
viru
hcv
rna
sampl
serum
tnfa
level
shown
chronic
hepatiwher
viru
undetect
neither
intens
ti
c
viru
hcv
infect
liver
damag
amount
hcv
rna
sehcv
singlestrand
rna
viru
infect
rum
cell
show
correl
level
liver
lymphoid
cell
hcv
infect
tnfa
transcript
peripher
mononuclear
cell
strong
tendenc
chronic
constitut
found
high
tnfa
valu
associ
genotyp
conclus
enhanc
common
caus
chronic
liver
diseas
western
express
tnfa
hcv
infect
high
level
world
thu
far
interferon
alfa
ifna
cytokin
may
play
role
resist
interferon
effect
antivir
agent
chronic
hepat
c
howtherapi
hepatolog
ever
treat
patient
respond
ifna
therapi
normal
serum
transtumor
necrosi
factor
tnfa
cytokin
proaminas
half
patient
relaps
interduc
primarili
activ
monocyt
lymphorupt
treatment
cyte
possess
pleiotrop
properti
particilittl
known
mechan
determin
pate
induct
immun
respons
sever
liver
damag
respons
ifna
hcv
infect
paper
studi
abbrevi
tnfa
tumor
necrosi
factor
mrna
messeng
rna
level
tnfa
serum
tnfa
transcript
pbmc
peripher
blood
mononuclear
cell
hcv
hepat
c
viru
ifna
liver
pbmc
patient
chronic
hepat
c
interferon
alfa
ut
untreat
group
sr
sustain
respons
rr
respons
relationship
cytokin
rewith
relaps
nr
respons
alt
alanin
aminotransferas
elisa
enzymelink
immunosorb
assay
rtpcr
revers
transcriptasepolymerspons
ifna
treatment
result
indic
ase
chain
reaction
cdna
complementari
dna
presenc
hcv
rna
liver
pbmc
year
patient
chronic
hepat
c
male
dle
baxter
deerfield
il
one
third
specimen
femal
age
rang
year
group
immedi
frozen
liquid
nitrogen
store
patient
includ
untreat
patient
patient
extract
rna
remain
use
studi
complet
treatment
ifna
histolog
studi
mu
daili
month
mu
time
week
analysi
serum
tnfa
level
analyz
serum
conmonth
respond
therapi
centrat
tnfa
use
elisa
cytoscreen
bioexhibit
sustain
biochem
remiss
diseas
sourc
intern
camarillo
ca
use
specif
antihumor
month
stop
ifna
administr
man
tnfa
antibodi
assay
perform
follow
addit
analyz
tnfa
mrna
level
pbmc
instruct
manufactur
sensit
limit
sampl
patient
chronic
hepat
c
male
assay
pgml
femal
age
rang
year
healthi
analysi
tnfa
mrna
level
analyz
tnfa
mrna
control
male
femal
age
rang
year
level
use
procedur
base
revers
transcripliv
biopsi
result
show
chronic
activ
hepat
tionpolymeras
chain
reaction
rtpcr
either
pbmc
cirrhosi
present
case
histolog
activliv
total
rna
mg
reversetranscrib
minut
iti
index
liver
sampl
determin
accord
knoat
u
mmulv
revers
transcriptas
brl
dell
score
system
twenti
patient
receiv
gaithersburg
md
ml
volum
rt
buffer
treatment
untreat
group
ut
studi
moll
trishcl
ph
moll
kcl
mmoll
mgcl
end
month
ifna
therapi
patient
supplement
mmoll
dithiothreitol
mmoll
deoxwer
classifi
accord
respons
ifna
three
ynucleosid
triphosph
ribonucleas
inhibitor
u
group
sustain
respons
sr
respons
relaps
rr
random
hexam
ng
boehring
mannheim
mannand
respons
nr
sr
group
n
includ
heim
germani
heat
min
quickchillpati
normal
alanin
aminotransferas
alt
valu
ing
ice
aliquot
complementari
dna
end
therapi
persist
normal
valu
cdna
pool
pbmc
liver
respect
use
pcr
year
followup
nr
group
n
includ
amplif
ml
pcr
buffer
mmoll
tristhos
patient
elev
alt
level
end
therapi
hcl
ph
mmoll
kcl
triton
conth
rr
group
n
includ
patient
normal
alt
tain
mmoll
deoxynucleosid
triphosph
mci
level
end
treatment
serum
alt
level
ml
p
deoxyeitidin
triphosph
amersham
buckincreas
interferon
withdraw
patient
inghamshir
england
upstream
downstream
primer
studi
perform
two
occas
initi
ng
mmoll
mgcl
u
taq
dna
polymertreat
ifna
end
therapi
ase
promega
corpor
md
blank
reaction
case
show
sustain
respons
treatment
fifteen
rna
perform
experi
pcr
amplif
addit
patient
show
persist
normal
serum
alt
fragment
bactin
cdna
use
ml
cdna
level
ifna
therapi
studi
month
pool
also
perform
intern
control
sampl
complet
treatment
case
refer
tnfa
cdna
fragment
amplifi
cycl
srpt
group
five
patient
also
studi
pbmc
liver
respect
minut
end
treatment
step
bactin
amplifi
cycl
sampl
liver
biopsi
patient
male
minut
step
protocol
avoid
femal
age
rang
year
chronic
hepat
c
interfer
plateau
effect
oligonucleotid
cirrhosi
studi
group
patient
gtcagatcatcttctcgaacc
cagatagatggwhom
also
pbmc
analyz
includ
ut
gctcatacc
upstream
downstream
primer
treat
subject
liver
biopsi
specimen
obrespect
use
amplif
bp
tain
end
month
therapi
nr
sr
fragment
nucleotid
human
tnfa
cdna
rr
normal
liver
sampl
obtain
control
tctacaatgagctgcgtgtg
ggtgaggatcttmal
femal
age
rang
year
laparotomi
catgaggt
primer
use
amplifi
frag
case
gallston
colon
ment
human
bactin
cdna
locat
nucanc
without
appar
liver
metastasi
cleotid
report
human
bactin
gene
patient
includ
present
studi
antihcvsequ
pcr
amplif
ml
aliquot
posit
use
enzymelink
immunosorb
assay
elisa
pcr
reaction
electrophores
agaros
gel
ortho
diagnost
system
secondgener
raritan
nj
band
visual
ethidium
bromid
equal
size
band
treatment
serum
excis
radioact
determin
obtain
hcv
rna
posit
use
revers
transcript
polymervalu
correct
background
radioact
ase
chain
reaction
caus
chronic
hepat
blank
reaction
rna
final
valu
correspond
exclud
tnfa
mrna
normal
bactin
mrna
prepar
pbmc
serum
liver
sampl
isoresult
express
countsperminut
cpm
ratio
lation
pbmc
fresh
blood
dilut
volum
tnfa
bactin
tnfa
mrna
valu
normalnacl
overlaid
lymphopr
nycom
pharma
ize
bactin
mrna
assum
bactin
oslo
norway
densiti
gml
centrifug
mrna
constantli
express
patient
chronic
minut
mononuclear
cell
layer
harhepat
c
patient
receiv
treatment
vest
interphas
wash
twice
nacl
treat
ifna
confirm
analyz
pbmc
lyse
moll
guanidinium
thiocyan
simultan
pbmc
liver
sampl
healthi
store
extract
total
rna
control
untreat
patient
treat
patient
perform
accord
method
chomczynski
differ
cpm
valu
correspond
bactin
mrna
sacchi
observ
group
pbmc
sampl
cpm
obtain
serum
sampl
venou
blood
collect
valu
ml
first
pcr
product
amplifi
cycl
use
inner
primer
ng
condit
first
pcr
amplif
aliquot
final
pcr
reaction
electrophores
agaros
gel
band
visual
ethidium
bromid
stain
sequenc
oligonucleotid
primer
chosen
five
noncod
region
hcv
genom
primer
hcv
cdna
synthesi
pcr
amplif
outer
sens
gtatctcgaggcgacactccaccatagat
outer
antisens
atactcgaggtgcacggtctacgagacct
inner
sens
ccaccatagatctctcccctgt
inner
antisens
cactctcgagcaccctatcaggcagt
hcv
rna
analysi
serum
ml
aliquot
extract
hcv
rna
revers
transcrib
random
primer
pcr
perform
use
condit
hcv
rna
quantifi
competit
pcr
techniqu
briefli
rna
ml
serum
mg
total
rna
pbmc
revers
transcrib
random
primer
valid
experi
pcr
assay
use
known
quantiti
total
rna
mg
perform
fig
cpm
valu
correspond
use
amount
either
tnfa
bactin
mrna
mg
tnfa
pbmc
liver
respect
mg
bactin
linear
rang
curv
analyz
whether
chang
tnfa
mrna
level
rel
bactin
result
chang
ratio
tnfa
pcr
product
cpmbactin
pcr
product
cpm
perform
rtpcr
mg
total
pbmc
rna
healthi
control
tnfa
bactin
respect
ad
serial
dilut
known
quantiti
tnfa
riboprob
pg
pg
tnfa
riboprob
obtain
runoff
transcript
plasmid
contain
insert
nucleotid
human
tnfa
cdna
shown
fig
increas
amount
tnfa
mrna
use
reaction
obtain
progress
increas
tnfabactin
ratio
increas
linear
pg
tnfa
riboprob
coeffici
interassay
variat
tnfabactin
ident
pcr
product
tnfa
cdna
amplif
verifi
first
southern
blot
analysi
use
plabel
pstibamhi
fragment
kblong
tnfa
cdna
hybrid
probe
second
digest
bglii
pvuii
ecori
two
former
enzym
yield
predict
restrict
fragment
ecori
digest
amplifi
pcr
product
restrict
site
endonucleas
present
amplifi
region
feron
treatment
serum
tnfa
level
higher
untreat
patient
chronic
hepat
c
pgml
fail
respond
ifn
month
treatment
pgml
healthi
control
pgml
p
patient
made
complet
sustain
biochem
respons
ifna
therapi
also
show
se
fig
transcript
express
tnfa
gene
ratio
rum
tnfa
level
pgml
significantli
bactin
pbmc
healthi
control
c
patient
higher
control
valu
p
although
chronic
hepat
c
without
treatment
ut
month
interferon
alfa
treatment
nr
patient
respons
intergroup
patient
serum
tnfa
tend
lower
feron
studi
end
treatment
rr
patient
complet
nonrespond
ifna
differ
atrespons
posttherapi
relaps
studi
end
tain
statist
signific
treatment
sr
patient
complet
respons
without
posttherapi
tnfa
mrna
level
ut
nr
rr
patient
relaps
sustain
respons
studi
end
treatment
srpt
patient
sustain
respons
studi
month
higher
healthi
control
pbmc
fig
complet
interferon
treatment
p
vs
ut
nr
rr
liver
fig
contrast
sr
patient
p
vs
sr
srpt
p
vs
sr
tnfa
mrna
valu
pmbc
liver
tissu
similar
control
significantli
lower
ut
nr
rr
patient
differ
hepat
ml
ml
volum
respect
revers
tranpbmc
tnfa
mrna
level
observ
among
scription
ml
cdna
serum
ml
cdna
last
three
group
patient
tnfa
gene
express
pbmc
mix
serial
dilut
competitor
dna
pbmc
srpt
group
similar
sr
molecul
serum
pbmc
differ
group
fig
cdna
interest
small
delect
base
fifteen
patient
ut
group
underw
ifnthi
competitor
dna
produc
clone
dna
therapi
experienc
sustain
respons
noncond
region
one
hcvinfect
patient
sampl
treatment
respond
ifna
amplifi
nest
pcr
two
set
primer
level
tnfa
mrna
pbmc
higher
patient
fail
outer
primer
ifna
patient
exhibit
insustain
respons
therapi
vs
ner
primer
pcr
cycl
perform
follow
denatur
second
anneal
second
extens
second
final
extens
minut
perkin
elmer
norwalk
ct
gene
amp
pcr
system
first
pcr
perform
mixtur
ml
first
pcr
product
transfer
second
pcr
mixtur
perform
ml
contain
mciml
p
deoxycitidin
triphosph
second
pcr
amplif
aliquot
pcr
reaction
electrophores
agaros
gel
band
visual
ethidium
bromid
equals
band
cdna
competitor
dna
excis
radioact
determin
compar
cpm
correspond
competitor
dna
correct
number
citosin
competitor
dna
differ
studi
cdna
copi
number
hcv
rna
sampl
consid
equal
copi
number
competitor
cpm
studi
cdnacpm
competitor
equal
hcv
genotyp
genotyp
perform
mean
hybrid
procedur
use
specif
probe
hcv
genotyp
accord
simmond
et
al
fig
transcript
express
tnfa
gene
ratio
amplifi
nest
pcr
product
hcv
core
region
bactin
liver
patient
chronic
hepat
c
c
probe
primer
techniqu
describ
viazov
normal
liver
initi
fig
fig
data
suggest
high
type
nr
respons
interferon
rr
complet
respons
postpretreat
tnfa
mrna
valu
associ
therapi
relaps
sr
sustain
complet
respons
lack
respons
ifna
five
patient
present
sustain
respons
ifna
tnfa
mrna
level
determin
pbmc
case
pbmc
sampl
patient
end
therapi
case
receiv
ifna
treatment
hcv
rna
present
one
substanti
reduct
level
pbmc
sampl
liver
biopsi
cytokin
transcript
treatment
specimen
see
tabl
treatment
two
slight
dea
shown
fig
patient
studi
creas
end
month
treatment
ifna
remain
two
slight
increas
divid
accord
presenc
absenc
hcv
overal
ifna
rna
liver
pbmc
shown
tnftreatment
induc
signific
chang
tnfa
mrna
valu
correspond
tissu
mrna
valu
group
patient
alreadi
higher
case
detect
hcv
rna
present
low
basal
level
tnfa
transcript
case
hcv
rna
neg
hcv
genotyp
perform
ut
patient
vs
p
pbmc
vs
patient
studi
end
ifna
therapi
p
liver
ut
patient
genotyp
observ
genotyp
patient
genotyp
patient
among
patient
studi
end
ifna
therapi
observ
untreat
patient
fig
sr
patient
studi
ifna
treatment
fig
consid
patient
correl
observ
tnfa
mrna
valu
measur
liver
pbmc
level
serum
aminotransferas
also
correl
tnfa
mrna
valu
knodel
score
liver
biopsi
result
similar
result
obtain
total
knodel
index
inflammatori
paramet
consid
studi
previou
report
show
hcv
observ
serum
hepatocyt
also
lymphoid
cell
result
indic
hcv
infect
associ
increas
transcript
express
tnfa
gene
liver
pbmc
high
serum
level
tnfa
induct
tnfa
gene
virus
shown
occur
varieti
vitro
model
well
divers
viral
diseas
includ
hbvand
hcvinduc
hepat
recent
shown
fig
level
tnfa
mrna
ratio
bactin
pbmc
product
tnfa
liver
take
place
liver
patient
chronic
hepat
c
end
nonparenchym
cell
also
hepatocyt
month
treatment
interferon
patient
divid
precis
stimulu
respons
enhanc
tnfa
accord
presenc
hcv
absenc
hcv
rna
gene
express
chronic
viral
hepat
correspond
specimen
defin
although
tnfa
may
gener
inflammatori
reaction
follow
immun
recognit
viral
antigen
mere
intracellular
presenc
evalu
whether
tnfa
gene
express
might
viral
compound
may
also
stimul
tnfa
gene
exb
relat
quantiti
viral
load
quantipress
builtin
defens
program
cell
fie
hcv
rna
serum
untreat
activ
neighbor
leukocyt
macrophag
patient
pbmc
subject
use
undergo
apoptosi
thu
limit
spread
infeca
competit
pcr
method
found
correl
tion
level
tnfa
mrna
pbmc
studi
find
correl
level
hcv
rna
serum
p
pbmc
p
activ
liver
diseas
level
tnfa
although
level
hcv
rna
treatgen
express
liver
pbmc
howev
ment
tend
higher
nr
sr
patient
observ
relationship
presenc
hcv
differ
signific
either
serum
rna
cell
valu
tnfa
transcript
copiesml
vs
copiesml
signific
thu
ut
patient
tnfa
mrna
level
shown
ns
pbmc
copiesmg
rna
vs
increas
liver
pbmc
hcv
copiesmg
rna
ns
rna
detect
site
wherea
sr
patnfa
gene
express
liver
damag
tnfa
tient
hcv
rna
absent
liver
transcript
liver
pbmc
similar
pbmc
major
case
tnfa
mrna
valpati
without
cirrhosi
vs
ue
compar
observ
normal
sub
vs
ns
comject
hand
nr
subject
rr
pare
tnfa
mrna
valu
liver
sampl
patient
hcv
rna
persist
liver
lymphoid
eight
rr
patient
low
activ
cell
end
treatment
case
liver
lesion
end
treatment
associ
enhanc
transcript
exfound
untreat
patient
high
activ
index
pression
tnfa
two
group
patient
liver
biopsi
specimen
former
group
idea
transcript
express
tnfknodel
index
liver
specimen
obtain
end
relat
intracellular
presenc
treatment
significantli
lower
latter
viru
activ
liver
diseas
supgroup
patient
vs
p
port
follow
observ
end
ifnbut
hepat
tnfa
mrna
valu
similar
therapi
serum
aminotransferas
level
equal
group
vs
ns
furthermor
normal
rr
sr
patient
wherea
tnfa
level
among
untreat
patient
five
subject
pbmc
liver
significantli
increas
minim
chang
liver
biopsi
result
mean
former
group
main
differ
histolog
activ
index
case
tnfa
two
group
patient
viral
persist
patient
mrna
level
pbmc
similar
observ
eventu
relaps
hand
ut
patient
show
activ
liver
lesion
estim
untreat
patient
activ
diseas
mean
hepal
wb
hepatolog
serum
transaminas
level
histolog
activ
tient
chronic
hepat
c
previous
resist
ifna
alon
data
could
specul
index
rr
patient
group
patient
similarli
increas
tnfa
mrna
level
high
tnfa
level
produc
oxid
stress
turn
stimul
tnfa
synthesi
caus
hcv
rna
detect
liver
tissu
lymphoid
cell
ifna
resist
would
explain
higher
tnfa
valu
observ
patient
insensit
ifna
although
presenc
viru
appear
determin
enhanc
tnfa
gene
express
neither
treatment
studi
need
determin
whether
pretreat
analysi
tnfa
gene
expreslevel
viremia
quantiti
hcv
rna
pbmc
shown
relat
amount
tnfa
transion
use
predict
respons
ifna
chronic
hepat
c
script
interestingli
serum
concentr
tnfa
observ
increas
untreat
acknowledg
thank
c
asensio
excelpati
patient
respond
ifnlent
technic
assist
treatment
also
although
lesser
extent
exhibit
sustain
complet
respons
